Overview

Study of Dara-Pembro for Multiple Myeloma Patients

Status:
Recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

This is a phase II, single-arm, open-label study in subjects with relapsed and/or refractory multiple myeloma (RRMM) comparing Pembrolizumab (Pembro) in combination with Daratumumab (Dara) to the historical control of Daratumumab.

Phase:

Phase 2

Details

Lead Sponsor:

Barry Paul
Saad Z. Usmani, MD

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab